Associated Genetic Biomarkers
Associated Diseases
Associated Pathways


Location [1]
Receptor tyrosine kinase/growth factor signaling, Kinase fusions
Protein [2]
Fibroblast growth factor receptor 3
Synonyms [1]

The fibroblast growth factor receptor 3 (FGFR3) gene encodes one member of the FGF receptor tyrosine kinase family, which includes four kinases: FGFR1, FGFR2, FGFR3, and FGFR4. FGFRs are involved in downstream signaling via the MAP kinase, JAK/STAT, and PI3K/AKT pathways. FGFR3 gene aberrations have been reported in urothelial, breast, head and neck, lung, brain, gastric, pancreatic, colorectal, kidney, endometrial, ovarian, and cervical cancers and are known to be highly prevalent in bladder cancers.

FGFR3 is altered in 2.21% of all cancers with bladder urothelial carcinoma, colon adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, and infiltrating renal pelvis and ureter urothelial carcinoma having the greatest prevalence of alterations [3].

FGFR3 GENIE Cases - Top Diseases

The most common alterations in FGFR3 are FGFR3 Mutation (2.66%), FGFR3 S249C (0.54%), FGFR3 Amplification (0.31%), FGFR3 R248C (0.14%), and FGFR3 Loss (0.13%) [3].

FGFR3 GENIE Cases - Top Alterations

Biomarker-Directed Therapies

Significance of FGFR3 in Diseases

Urothelial Carcinoma +

Bladder Carcinoma +

Multiple Myeloma +

Malignant Solid Tumor +

Plasma Cell Leukemia +

Non-Small Cell Lung Carcinoma +

Breast Carcinoma +

Cancer +

Non-Hodgkin Lymphoma +

Cholangiocarcinoma +

Acute Myeloid Leukemia +

Chronic Lymphocytic Leukemia +

Myelodysplastic Syndromes +

Smoldering Plasma Cell Myeloma +

Transitional Cell Carcinoma +

Squamous Cell Lung Carcinoma +

Endometrial Carcinoma +

Gastric Carcinoma +

Acute Lymphoblastic Leukemia +

Chronic Myeloid Leukemia +

Bladder Urothelial Carcinoma +

Colorectal Carcinoma +

Lymphoma +

Adenocarcinoma Of The Gastroesophageal Junction +

Chronic Myelomonocytic Leukemia +

Head And Neck Squamous Cell Carcinoma +

Hodgkin Lymphoma +

Myeloproliferative Neoplasm +

Urethral Urothelial Carcinoma +

Oropharyngeal Squamous Cell Carcinoma +

Melanoma +

Anaplastic Astrocytoma +

Oral Cavity Squamous Cell Carcinoma +

Malignant Uterine Neoplasm +

Malignant Glioma +

Gastric Adenocarcinoma +

Glioblastoma +

Glioma +

Myeloid Neoplasm +

B-Cell Non-Hodgkin Lymphoma +

Lung Carcinoma +

Ovarian Carcinoma +

Lymphocytic Neoplasm +

Bile Duct Carcinoma +

Invasive Breast Carcinoma +

Pancreatic Carcinoma +

Sarcoma +

Anaplastic Oligodendroglioma +

Aplastic Anemia +

Bladder Papillary Urothelial Carcinoma +

Bronchogenic Carcinoma +

Cervical Carcinoma +

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma +

Diffuse Large B-Cell Lymphoma +

Double-Hit Lymphoma +

Esophageal Carcinoma +

Esophageal Squamous Cell Carcinoma +

Extrahepatic Cholangiocarcinoma +

Gallbladder Carcinoma +

Head And Neck Carcinoma +

Histiocytic And Dendritic Cell Neoplasm +

Hypopharyngeal Squamous Cell Carcinoma +

Infiltrating Renal Pelvis And Ureter Urothelial Carcinoma +

Intrahepatic Cholangiocarcinoma +

Laryngeal Squamous Cell Carcinoma +

Lymphoblastic Lymphoma +

Mantle Cell Lymphoma +

Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma +

Myelodysplastic/Myeloproliferative Neoplasm +

Myelofibrosis +

Myeloma +

Oral Cavity Carcinoma +

Plasmacytoma +

Prolymphocytic Leukemia +

Renal Pelvis Urothelial Carcinoma +

Renal Pelvis And Ureter Carcinoma +

Small Cell Lung Carcinoma +

Small Lymphocytic Lymphoma +

Stage 0is Bladder Urothelial Carcinoma +

T-Cell Prolymphocytic Leukemia +

Therapy-Related Chronic Myelomonocytic Leukemia +

Therapy-Related Myelodysplastic Syndrome +

Triple-Hit Lymphoma +

Ureter Urothelial Carcinoma +

Waldenstrom Macroglobulinemia +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015.

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.